Ocular Therapeutix Inc

NASDAQ:OCUL  
6.17
-0.34 (-5.22%)
Earnings Announcements

Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results And Business Update

Published: 11/08/2021 21:18 GMT
Ocular Therapeutix Inc (OCUL) - Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update.
Qtrly Loss per Share $0.23.
Q3 Earnings per Share View $-0.27 -- Refinitiv Ibes Data (analyst estimates).
Ocular Therapeutix - Expect to Announce Phase 2 Clinical Trial Topline Results for Otx-ded, Our Clinical Trial in Episodic Dry Eye Disease in Q1 of 2022.
Revenue is expected to be $14.44 Million
Adjusted EPS is expected to be -$0.23

Next Quarter Revenue Guidance is expected to be $16.92 Million
Next Quarter EPS Guidance is expected to be -$0.21

More details on our Analysts Page.